Diamond-Blackfan Anemia CRISPR Cell Models for Drug Discovery

Diamond-Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome with an estimated incidence of 5-7 per million live births (WHO, 2023). The disease typically presents in infancy or early childhood, with a median age at diagnosis of 2 months. Approximately 90% of patients are diagnosed by 1 year of age. The 5-year survival rate for DBA patients is approximately 75-80% (NCI SEER data, 2020), with mortality primarily due to complications of severe anemia, infections, and development of malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Key risk factors include heterozygous loss-of-function mutations in ribosomal protein (RP) genes, with RPS19 mutations accounting for about 25% of cases. Other commonly mutated RP genes include RPL5, RPL11, RPS10, RPS26, and RPS24. The disease is characterized by a failure of erythropoiesis, leading to macrocytic anemia, reticulocytopenia, and a selective decrease in erythroid progenitors in the bone marrow. Approximately 30-50% of patients have congenital anomalies, including craniofacial abnormalities, thumb malformations, and cardiac defects.

DBA is an ideal model for studying ribosomopathies, a class of diseases caused by defects in ribosome biogenesis or function. The monogenic nature of most DBA cases (single RP gene mutations) allows for clear genotype-phenotype correlations and straightforward genetic modeling. Publicly available datasets, such as those from the Diamond-Blackfan Anemia Registry (DBAR) and the NCBI Gene database, provide extensive mutation and clinical data. Open research questions include: (1) the mechanism by which RP haploinsufficiency selectively impairs erythroid differentiation, (2) the role of p53 activation in disease pathogenesis, (3) the basis for variable penetrance and expressivity, and (4) the development of targeted therapies that bypass the ribosomal defect (e.g., L-leucine, corticosteroids, gene therapy).

The pathogenesis of DBA involves a cascade of events initiated by ribosomal protein haploinsufficiency:

1. Ribosome Biogenesis Defect: Mutations in RP genes (e.g., RPS19, RPL5) impair the assembly of the small (40S) or large (60S) ribosomal subunit, leading to reduced ribosome numbers and global protein synthesis defects.

2. Nucleolar Stress and p53 Activation: Accumulation of free ribosomal proteins (e.g., RPL5, RPL11) binds to MDM2, inhibiting p53 degradation. This activates the p53 pathway, leading to cell cycle arrest and apoptosis, particularly in erythroid progenitor cells.

3. Selective Erythroid Failure: The erythroid lineage is especially sensitive to ribosomal stress due to the high demand for globin protein synthesis. Reduced translation of key erythroid transcription factors (e.g., GATA1) exacerbates the differentiation block.

4. Impaired Hematopoietic Stem Cell (HSC) Function: RP haploinsufficiency also affects HSC self-renewal and maintenance, contributing to bone marrow failure.

Data from NCBI Gene, ClinVar (2024), and COSMIC (v100).

Key signaling networks deregulated in DBA include:

• • p53 Pathway: Central to DBA pathogenesis. Activated by nucleolar stress, leading to apoptosis and cell cycle arrest. Key nodes: MDM2, p53, p21, BAX.
• • c-MYC Pathway: c-MYC transcription is sensitive to ribosome availability. Reduced translation of c-MYC impairs cell proliferation and erythroid differentiation.
• • mTOR Signaling: mTOR activity is often downregulated due to reduced amino acid sensing and translation capacity, further suppressing protein synthesis.
• • GATA1 Pathway: GATA1, a master regulator of erythropoiesis, is translationally repressed in DBA, leading to a block in erythroid differentiation.
• • TGF-β/SMAD Pathway: Altered TGF-β signaling contributes to bone marrow fibrosis and impaired hematopoiesis in some patients.

Organoid models: Erythroid organoids derived from patient iPSCs or CD34+ cells recapitulate the erythroid differentiation block and allow for drug testing in a 3D context.

• • Zebrafish models: Morpholino or CRISPR-mediated knockdown of rps19 or rpl5 causes anemia and developmental defects, mimicking DBA.
• • Mouse models: Conditional knockout of Rps19 in hematopoietic cells leads to macrocytic anemia and bone marrow failure. Inducible shRNA models allow temporal control of RP gene knockdown.
• • Patient-derived xenograft (PDX) models: Limited due to the difficulty of engrafting DBA HSCs; however, iPSC-derived HSC xenografts are emerging.

CRISPR-Cas9 gene editing enables the generation of isogenic cell lines with defined RP gene mutations, providing powerful tools for studying DBA pathogenesis. Examples include:

• • RPS19 knockout K562 cells: Created by introducing frameshift mutations in exon 2 of RPS19. These cells show reduced ribosome biogenesis, impaired proliferation, and increased p53 activation.
• • RPL5 knockout UT-7 cells: Model the effects of RPL5 haploinsufficiency on erythroid differentiation.
• • RPS19 R62W knock-in models: Introduce a common missense mutation found in DBA patients to study dominant-negative effects.

Commercially available, sequence-verified gene-edited cell lines accelerate research by providing reproducible, isogenic backgrounds for functional studies and drug screening.

Knockout and knock-in cell lines are used to validate the role of RP genes in erythropoiesis. For example, RPS19 knockout in K562 cells confirmed that loss of RPS19 reduces globin expression and increases apoptosis. Complementing with wild-type RPS19 cDNA rescues the phenotype, confirming specificity.

Isogenic pairs (e.g., RPS19 wild-type vs. knockout) are used in high-throughput screens to identify compounds that rescue erythroid differentiation. For instance, L-leucine and dexamethasone have been shown to improve hemoglobinization in RPS19-deficient cells. Resistance mechanisms to corticosteroids can be studied by exposing isogenic lines to drug pressure and sequencing for secondary mutations.

CRISPR-based synthetic lethality screens in RPS19-deficient cells identify genes whose loss is selectively lethal in the DBA context. For example, depletion of MDM2 (a p53 inhibitor) is synthetically lethal with RPS19 loss, suggesting MDM2 inhibitors as potential therapeutics. Such screens also reveal biomarkers of disease progression, such as elevated p53 target gene expression.